ResMed to Celebrate 30th Anniversary and 20 Years Listed on the New York Stock Exchange by Ringing The Opening Bell® on September 30, 2019

Download as PDF

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick Farrell will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Monday, September 30, 2019 at 9:30 a.m. ET. Farrell will be joined on the bell podium with other members of the ResMed management team to celebrate 20 years of being listed on the NYSE and to commemorate ResMed’s 30th anniversary.

Founded in 1989, ResMed began as ResCare, a management buy-out of sleep apnea technology from Baxter Healthcare. Today, ResMed is the world’s leading software-driven medical device company with over 4.5 billion nights of medical sleep and respiratory care data and over 10 million 100% cloud connectable medical devices in the market.

“From a single A$1.25 million investment, ResMed has transformed into a A$28 billion (US$19 billion) connected health leader, changing over 100 million lives a year with either a cloud-connected medical device or through software support of an out-of-hospital care agency,” said Farrell. “I’m proud to be one of 7,500-plus ResMedians worldwide dedicated to improving the quality of so many lives, and one of countless investors who have long seen and supported the value of all that ResMed creates. And we are just getting started.”

The event will be broadcast live from the NYSE and will be live streamed online at https://www.nyse.com/bell.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com

Source: ResMed

Released September 26, 2019